Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma

Table 2 Summary of somatic mutation counts by whole-exome sequencing

Case	Sample ID	Total Somatic Mutations	Exonic Mutations	Synonymous SNV	Non- synonymous SNV	stoploss/ stopgain	Shared pre + post-NACT (position)^a	Shared pre + post-NACT (gene)^b
1 (R)	1-1 (pre)	333	71	24	47	0	13% (6/47)	17% (8/47)
1 (R)	1-2 (post)	5652	1735	904	821	10	1% (6/831)	1% (8/691)
2 (R)	2-1 (pre)	427	116	34	77	5	41% (34/82)	41% (33/80)
2 (R)	2-2 (post)	543	120	45	73	2	45% (34/75)	51% (33/65)
3 (R)	3-1 (pre)	399	65	25	38	2	65%^c (26/40)	68%^c (27/40)
	3-2 (post)	351	61	27	32	2	62%^d (21/34)	64%^d (21/33)
	3-3 (post)	298	55	23	31	1	41%^d (13/32)	47%^d (14/30)
4 (S)	4-1 (pre)	539	128	33	88	7	43% (41/95)	44% (42/95)
4 (S)	4-2 (post)	510	137	39	92	6	42% (41/98)	43% (42/98)
5 (S)	5-1 (pre)	1412	436	216	211	9	16% (35/220)	17% (35/209)
5 (S)	5-2 (post)	703	106	35	69	2	49% (35/71)	58% (35/60)

Total number of somatic mutations detected in pre and post-NACT tumor samples using whole-exome sequencing. The numbers of exonic and non-synonymous exonic mutations (including mutations classified as non-synonymous SNV, stopgain or stoploss) are highlighted, in addition to the overlap of non-synonymous mutations in pre-NACT and post-NACT samples from the same patient
^acomparison made based on genomic position
^bcomparison made based on gene name
^cmutations shared with at least one post-NACT sample from same case
^dmutations shared with pre-NACT sample from same case
Abbreviations: NACT Neoadjuvant chemotherapy; R platinum-resistant case, S - platinum-sensitive case, SNV Single nucleotide variant

ISSN: 1757-2215